Correlation between Neutrophil Gelatinase Associated with Lipocaline and Beta-2 Microglobulin with Other Renal Markers in Iraqi Patients with Multiple Myeloma

Inas Nazeeh Abed; Usama Salman Al-timari; Hiba Abid Al-Hussein hassan; Abbas Thamer Dwayyikh

doi:10.51173/jt.v4i33.679

Authors

Inas Nazeeh Abed Medical Laboratory Science Technologist, Medical City, Baghdad Teaching Hospital, Baghdad, Iraq
Usama Salman Al-timari Department of Medical Laboratory Technology, Al-Nisour University College, Baghdad, Iraq
Hiba Abid Al-Hussein hassan College of Health & Medical Technology - Baghdad, Middle Technical University, Baghdad, Iraq
Abbas Thamer Dwayyikh Specialist Medical Laboratory Technologist, Medical City, National Center For Teaching Laboratories (NCFTL), Baghdad, Iraq

DOI:

https://doi.org/10.51173/jt.v4i33.679

Keywords:

Multiple myeloma (MM), Neutrophil gelatinase-associated lipocalin (NGAL), ß2-Microglobulin (ß2M), Urea, Creatinine

Abstract

Multiple myeloma, often known as myeloma, is a kind of bone marrow cancer. The bone marrow is a spongy tissue in the middle of some bones that creates the body's blood cells. The current study is designed to find the correlation between Neutrophil gelatinase-associated lipocalin and ß2-Microglobulin with other renal markers among patients with multiple myeloma and healthy people. One hundred twenty patients with multiple myeloma and sixty healthy control were attending the National Center for Teaching Laboratories (NCFTL), Baghdad Hospital Advisory (BHA), and Baghdad Teaching Hospital. For the period from November 2021 to March 2022. Information taken from patients involved age, genus, drugs used, and other medical details. Multiple myeloma disease was diagnosed using symptoms, biochemical testing, x-ray, and clinical examination by specialists. Then serum urea, creatinine, total protein, globulin, and albumin are done by Autoanalyzer. Furthermore, Neutrophil gelatinase-associated lipocalin and ß2-Microglobulin were done by ELISA technique. The present study found that the male patients in the age range (60-69) and (50-59) years had a higher percentage (30%, 20% and 36%,16.7%) than female patients in both studied groups. The multiple myeloma disease patients with urea and creatinine above normal had a highly significant increase (p= 0.000) in the mean ± SD of urea, creatinine, total protein, globulin, Beta 2 microglobulin, and Neutrophil gelatinase-associated lipocalin (57.83±30.92 mg/dl, 2.09±1.38 mg/dl, 77.95±13.08 g/l, 42.52±11.16 g/l, 39.14±16.20, 452.50±188.83) respectively. In addition, patients with urea and creatinine normal had a highly significant increase (p= 0.000) in the mean ± SD of creatinine, total protein, Globulin, Beta 2 microglobulin, and Neutrophil gelatinase-associated lipocalin (0.80±0.20 mg/dl, 73.07±11.75 g/l, 40.34±10.67 g/l, 43.28±18.78, 432.77±198.45) respectively compared with the healthy controls.

Downloads

Download data is not yet available.

References

Woziwodzka, K. et al ,2020; ‘New Markers of Renal Failure in Multiple Myeloma and Monoclonal Gammopathies’, Journal of Clinical Medicine, 9(6), p. 1652. doi: 10.3390/jcm9061652.

Guo, L. et al. ,2020; ‘Evaluation of serum neutrophil gelatinase-associated lipocalin in older patients with chronic kidney disease’, Aging Medicine, 3(1), pp. 32–39. doi: 10.1002/agm2.12098.

Matsa, R. et al. ,2014; ‘Plasma and urine neutrophil gelatinase-associated lipocalin in the diagnosis of new onset acute kidney injury in critically ill patients’, Critical Care, 18(4), pp. 1–10. doi: 10.1186/cc13958.

For, U. (For ,Useful) Algorithm. 2022; ‘Test Definition : B2M Test Definition : B2M’, pp. 2–4.

C J van de Donk, N. W., Pawlyn, C. and Yong, K. L. ,2021; Seminar Multiple myeloma, www.thelancet.com. Available at: www.thelancet.com.Cancer.Net (2018) Multiple Myeloma: Risk Factors and Prevention, Cancer.Net. Available at: www.cancer.org/cancer/cancer-causes/diet-physical-activity/body-weight-and-.Candido, S. et al. (2014) ‘Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer’, Oncotarget, 5(6), pp. 1576–1594. doi: 10.18632/oncotarget.1738.

Zhao, Ranran; Xie,Yiyu; Yang,Bingyu; Wang,Chang and Han,Yue. 2020; ‘Identification of metabolic biomarkers to predict treatment outcome and disease progression in multiple myeloma.’, American journal of cancer research, 10(11), pp. 3935–3946.

J. J. Carrero, M. Hecking, N. C. Chesnaye, and K. J. Jager, 2018; “Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease,” Nat. Rev. Nephrol., vol. 14, no. 3, pp. 151–164, doi: 10.1038/nrneph.2017.181.

Alexander DD, Mink PJ, Adami HO, Cole P, Mandel JS, Oken, 2007; MM, Multiple myeloma: a review of the epidemiologic literature. Int J Cancer;120(Suppl 12):40–61.

Morris et al., “基因的改变NIH Public Access,” 2015;Gerontology, vol. 61, no. 6, pp. 515–525, doi: 10.1053/j.ajkd.2009.12.034.Acute.

F. Fei, T. Ma, X. Zhou, M. Zheng, B. Cao, and J. Li, 2021; “Metabolic markers for diagnosis and risk-prediction of multiple myeloma,” Life Sci., vol. 265, p. 118852, doi: 10.1016/j.lfs.2020.118852.

A. G. Andronesi ,Andreea G.,Tanase, Alina D., Sorohan. 2019; “Incidence and risk factors for acute kidney injury following autologous stem cell transplantation for multiple myeloma,” Cancer Med., vol. 8, no. 6, pp. 3278–3285, doi: 10.1002/cam4.2187.

A. S. Salman, E. S. Salaha, and M. S. Abass, 2020; “Estimation of beta two microglobulins, Fetuin-A, resistin serum level in iraqi multiple myeloma patients,” Iraqi J. Pharm. Sci., vol. 29, no. 2, pp. 80–87, doi: 10.31351/vol29iss2pp80-87.

T. Van Donge et al., 2021; “Age appropriate reference intervals for eight kidney function and injury markers in infants, children and adolescents,” Clin. Chem. Lab. Med., vol. 59, no. 2, pp. 373–382, doi: 10.1515/cclm-2020-0781.

H. Chae, H. Ryu, K. Cha, M. Kim, Y. Kim, and C. K. Min, 2015; “Neutrophil gelatinase-associated lipocalin as a biomarker of renal impairment in patients with multiple myeloma,” Clin. Lymphoma, Myeloma Leuk., vol. 15, no. 1, pp. 35–40, doi: 10.1016/j.clml.2014.07.014.

D. Press, 2013; “Correlation of serum neutrophil gelatinase- associated lipocalin with acute kidney injury in hypertensive disorders of pregnancy,” pp. 181–186.

S. Xiong, T. Qi, N. Gong, and C. Yang, 2021; “Correlation and Diagnostic Value of Serum RBP4 and sRAGE and the Condition of Patients with Chronic Kidney Disease,” Evidence-based Complement. Altern. Med., vol. 2021, doi: 10.1155/2021/6166528.

M. Makridakis et al., 2020; “Multiplexed MRM-based protein quantification of putative prognostic biomarkers for chronic kidney disease progression in plasma,” Sci. Rep., vol. 10, no. 1, pp. 1–12, doi: 10.1038/s41598-020-61496-z.

K. Suzuki, 2012; “Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion,” Clin. Exp. Nephrol., vol. 16, no. 5, pp. 659–671, doi: 10.1007/s10157-012-0684-5.